Target Price | $97.85 |
Price | $63.30 |
Potential |
54.58%
register free of charge
|
Number of Estimates | 26 |
26 Analysts have issued a price target Biomarin Pharmaceutical 2026 .
The average Biomarin Pharmaceutical target price is $97.85.
This is
54.58%
register free of charge
$126.00
99.05%
register free of charge
$65.00
2.69%
register free of charge
|
|
A rating was issued by 31 analysts: 25 Analysts recommend Biomarin Pharmaceutical to buy, 6 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Biomarin Pharmaceutical stock has an average upside potential 2026 of
54.58%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion $ | 2.84 | 3.14 |
17.35% | 10.52% | |
EBITDA Margin | 22.06% | 28.12% |
78.58% | 27.49% | |
Net Margin | 14.85% | 19.28% |
114.00% | 29.84% |
26 Analysts have issued a sales forecast Biomarin Pharmaceutical 2025 . The average Biomarin Pharmaceutical sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Biomarin Pharmaceutical EBITDA forecast 2025. The average Biomarin Pharmaceutical EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
19 Biomarin Pharmaceutical Analysts have issued a net profit forecast 2025. The average Biomarin Pharmaceutical net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | 2.21 | 3.17 |
151.14% | 43.44% | |
P/E | 19.96 | |
EV/Sales | 3.71 |
19 Analysts have issued a Biomarin Pharmaceutical forecast for earnings per share. The average Biomarin Pharmaceutical EPS is
This results in the following potential growth metrics and future valuations:
Biomarin Pharmaceutical...
Analyst | Rating | Action | Date |
---|---|---|---|
Oppenheimer |
Locked
➜
Locked
|
Locked | Feb 24 2025 |
Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
B of A Securities |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
RBC Capital |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
Citigroup |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
Scotiabank |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
Piper Sandler |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
Analyst Rating | Date |
---|---|
Locked
Oppenheimer:
Locked
➜
Locked
|
Feb 24 2025 |
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Feb 20 2025 |
Locked
B of A Securities:
Locked
➜
Locked
|
Feb 20 2025 |
Locked
RBC Capital:
Locked
➜
Locked
|
Feb 20 2025 |
Locked
Citigroup:
Locked
➜
Locked
|
Feb 20 2025 |
Locked
Scotiabank:
Locked
➜
Locked
|
Feb 20 2025 |
Locked
Piper Sandler:
Locked
➜
Locked
|
Feb 20 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.